FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016170717> ?p ?o ?g. }

• W2016170717 endingPage "522" @default.
• W2016170717 startingPage "518" @default.
• W2016170717 abstract "No standard second-line treatments are available for hepatocellular carcinoma patients who fail sorafenib therapy. We assessed the safety and efficacy of metronomic capecitabine after first-line sorafenib failure.Retrospective analysis of consecutive hepatocellular carcinoma patients receiving metronomic capecitabine between January 2012 and November 2014. The primary end-point was safety, secondary end-point was efficacy, including time-to-progression and overall survival.Twenty-six patients (80% Child-Pugh A, 80% Barcelona Clinic Liver Cancer stage C) received metronomic capecitabine (500 mg/bid). Median treatment duration was 3.2 months (range 0.6-31). Fourteen (53%) patients experienced at least one adverse event. The most frequent drug-related adverse events were bilirubin elevation (23%), fatigue (15%), anaemia (11%), lymphoedema (11%), and hand-foot syndrome (7.6%). Treatment was interrupted in 19 (73%) for disease progression, in 4 (15%) for liver deterioration, and in 1 (3.8%) for adverse event. Disease control was achieved in 6 (23%) patients. Median time-to-progression was 4 months (95% confidence interval 3.2-4.7). Median overall survival was 8 months (95% confidence interval 3.7-12.3).Metronomic capecitabine was well tolerated in hepatocellular carcinoma patients who had been treated with sorafenib. Preliminary data show potential anti-tumour activity with long-lasting disease control in a subgroup of patients that warrants further evaluation in a phase III study." @default.
• W2016170717 created "2016-06-24" @default.
• W2016170717 creator A5026985433 @default.
• W2016170717 creator A5029721718 @default.
• W2016170717 creator A5032593836 @default.
• W2016170717 creator A5037368479 @default.
• W2016170717 creator A5050694729 @default.
• W2016170717 creator A5068348071 @default.
• W2016170717 creator A5079044895 @default.
• W2016170717 creator A5084769321 @default.
• W2016170717 date "2015-06-01" @default.
• W2016170717 modified "2023-09-23" @default.
• W2016170717 title "Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure" @default.
• W2016170717 cites W1524238852 @default.
• W2016170717 cites W1739036892 @default.
• W2016170717 cites W1970545762 @default.
• W2016170717 cites W1971837077 @default.
• W2016170717 cites W1976195505 @default.
• W2016170717 cites W1994193851 @default.
• W2016170717 cites W2004969691 @default.
• W2016170717 cites W2018822308 @default.
• W2016170717 cites W2022665891 @default.
• W2016170717 cites W2024450952 @default.
• W2016170717 cites W2034084175 @default.
• W2016170717 cites W2036298536 @default.
• W2016170717 cites W2038834437 @default.
• W2016170717 cites W2051684210 @default.
• W2016170717 cites W2054055814 @default.
• W2016170717 cites W2057812738 @default.
• W2016170717 cites W2079586464 @default.
• W2016170717 cites W2084667393 @default.
• W2016170717 cites W2087675944 @default.
• W2016170717 cites W2089449278 @default.
• W2016170717 cites W2111215313 @default.
• W2016170717 cites W2123546830 @default.
• W2016170717 cites W2140587309 @default.
• W2016170717 cites W2146324931 @default.
• W2016170717 cites W2153280781 @default.
• W2016170717 cites W2160868294 @default.
• W2016170717 cites W2165901246 @default.
• W2016170717 cites W2169965478 @default.
• W2016170717 cites W4231964547 @default.
• W2016170717 cites W4245784696 @default.
• W2016170717 cites W91733645 @default.
• W2016170717 cites W9288866 @default.
• W2016170717 doi "https://doi.org/10.1016/j.dld.2015.03.010" @default.
• W2016170717 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25861840" @default.
• W2016170717 hasPublicationYear "2015" @default.
• W2016170717 type Work @default.
• W2016170717 sameAs 2016170717 @default.
• W2016170717 citedByCount "57" @default.
• W2016170717 countsByYear W20161707172015 @default.
• W2016170717 countsByYear W20161707172016 @default.
• W2016170717 countsByYear W20161707172017 @default.
• W2016170717 countsByYear W20161707172018 @default.
• W2016170717 countsByYear W20161707172019 @default.
• W2016170717 countsByYear W20161707172020 @default.
• W2016170717 countsByYear W20161707172021 @default.
• W2016170717 countsByYear W20161707172022 @default.
• W2016170717 countsByYear W20161707172023 @default.
• W2016170717 crossrefType "journal-article" @default.
• W2016170717 hasAuthorship W2016170717A5026985433 @default.
• W2016170717 hasAuthorship W2016170717A5029721718 @default.
• W2016170717 hasAuthorship W2016170717A5032593836 @default.
• W2016170717 hasAuthorship W2016170717A5037368479 @default.
• W2016170717 hasAuthorship W2016170717A5050694729 @default.
• W2016170717 hasAuthorship W2016170717A5068348071 @default.
• W2016170717 hasAuthorship W2016170717A5079044895 @default.
• W2016170717 hasAuthorship W2016170717A5084769321 @default.
• W2016170717 hasConcept C121608353 @default.
• W2016170717 hasConcept C126322002 @default.
• W2016170717 hasConcept C141071460 @default.
• W2016170717 hasConcept C143998085 @default.
• W2016170717 hasConcept C168563851 @default.
• W2016170717 hasConcept C197934379 @default.
• W2016170717 hasConcept C203092338 @default.
• W2016170717 hasConcept C2777909004 @default.
• W2016170717 hasConcept C2778019345 @default.
• W2016170717 hasConcept C2778695046 @default.
• W2016170717 hasConcept C526805850 @default.
• W2016170717 hasConcept C71924100 @default.
• W2016170717 hasConcept C90924648 @default.
• W2016170717 hasConceptScore W2016170717C121608353 @default.
• W2016170717 hasConceptScore W2016170717C126322002 @default.
• W2016170717 hasConceptScore W2016170717C141071460 @default.
• W2016170717 hasConceptScore W2016170717C143998085 @default.
• W2016170717 hasConceptScore W2016170717C168563851 @default.
• W2016170717 hasConceptScore W2016170717C197934379 @default.
• W2016170717 hasConceptScore W2016170717C203092338 @default.
• W2016170717 hasConceptScore W2016170717C2777909004 @default.
• W2016170717 hasConceptScore W2016170717C2778019345 @default.
• W2016170717 hasConceptScore W2016170717C2778695046 @default.
• W2016170717 hasConceptScore W2016170717C526805850 @default.
• W2016170717 hasConceptScore W2016170717C71924100 @default.
• W2016170717 hasConceptScore W2016170717C90924648 @default.
• W2016170717 hasIssue "6" @default.
• W2016170717 hasLocation W20161707171 @default.
• W2016170717 hasLocation W20161707172 @default.

• next